Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: Pharmacokinetic modelling analysis of interaction between a soluble target and a drug

Clinical Pharmacokinetics

Volumn 51, Issue 7, 2012, Pages 443-455

  Stepensky, David ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

adalimumab; antirheumatics; intra articular; intravenous; pharmacokinetic modelling; rheumatoid arthritis; subcutaneous; Tumour necrosis factor alpha

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMPUTER SIMULATION; HUMANS; JOINTS; MODELS, BIOLOGICAL; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861666335     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11599970-000000000-00000     Document Type: Article

References (47)

1. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2011; 49 (8): 493-507
2. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008 Nov; 84 (5): 548-58
3. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies: mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007 Jan; 10 (1): 84-96 (Pubitemid 46438261)
4. Davda JP, Jain M, Batra SK, et al. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 2008 Mar; 8 (3): 401-13 (Pubitemid 351221431)
5. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 2010 Mar; 99 (3): 1582-600
6. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994 Sep; 56 (3): 248-52 (Pubitemid 24323915)
7. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001 Dec; 28 (6): 507-32 (Pubitemid 34289541)
8. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 2009 Jul; 5 (7): 803-12
9. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005 Oct; 22 (10): 1589-96 (Pubitemid 41355898)
10. Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the targetmediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008 Oct; 35 (5): 573-91
11. Greischel A, Zahn G. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. J Pharmacol Exp Ther 1989 Oct; 251 (1): 358-61 (Pubitemid 19261987)
12. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010 Jul; 49 (7): 1215-28
13. Bocci V, Pacini A, Pessina GP, et al. Studies on tumor necrosis factor (TNF): I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration. Gen Pharmacol 1987; 18 (4): 343-6 (Pubitemid 17117376)
14. Ferraiolo BL, Moore JA, Crase D, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab Dispos 1988 Mar-Apr; 16 (2): 270-5
15. Ferraiolo BL, McCabe J, Hollenbach S, et al. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats: effects of size and number of doses and nephrectomy. Drug Metab Dispos 1989 Jul-Aug; 17 (4): 369-72 (Pubitemid 19206576)
16. Gamm H, Lindemann A, Mertelsmann R, et al. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 1991; 27 (7): 856-63
17. Mittelman A, Puccio C, Gafney E, et al. A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 1992 Aug; 10 (3): 183-90
18. McNearney T, Baethge BA, Cao S, et al. Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004 Sep; 137 (3): 621-7 (Pubitemid 39128094)
19. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005 Jul-Aug; 23 (4): 469-74 (Pubitemid 41447616)
20. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011 Jul; 70 (7): 1208-15
21. Humira-(adalimumab) prescribing information. Abbott Park (IL): Abbott, 2011 Mar
22. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29 (11): 2288-98 (Pubitemid 35266018)
23. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factoralpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003 Jun; 25 (6): 1700-21 (Pubitemid 36801943)
24. Hollensen C. Meta-analysis of tumour necrosis factor-inhibitor treatment for rheumatoid arthritis [thesis]. Kongens Lyngby: Technical University of Denmark, 2009
25. Jamar F, Houssiau FA, Devogelaer J-P, et al. Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 53-61 (Pubitemid 34537921)
26. Kinne RW, Becker W, Simon G, et al. Joint uptake and body distribution of a technetium-99m-labeled anti-rat-CD4 monoclonal antibody in rat adjuvant arthritis. J Nucl Med 1993 Jan; 34 (1): 92-8 (Pubitemid 23014232)
27. Fisher BAC, Keat A. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis? J Rheumatol 2006; 33 (10): 1934-5 (Pubitemid 44571863)
28. Nikas SN, Temekonidis TI, Zikou AK, et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis 2004 Jan; 63 (1): 102-3 (Pubitemid 38064614)
29. Conti F, Priori R, Chimenti MS, et al. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005 Apr; 52 (4): 1224-6 (Pubitemid 40530130)
30. van der Bijl AE, Teng YK, van Oosterhout M, et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum 2009 Jul 15; 61 (7): 974-8
31. Kobak S. Osteonecrosis and monoarticular rheumatoid arthritis treated with intra-articular adalimumab. Mod Rheumatol 2008; 18 (3): 290-2
32. Pejovic M, Stankovic A, Mitrovic DR. Determination of the apparent synovial permeability in the knee joint of patients suffering from osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1995 Jun; 34 (6): 520-4
33. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009 May; 131 (2): 308-16
34. Altman RD. Laboratory findings in osteoarthritis. In: Moskowitz RW, Altman RD, Hochberg MC, et al., editors. Osteoarthritis: diagnosis and medical/surgical management. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2007: 204
35. Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010 Sep; 99 (3): 306-14
36. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: relationships with indirect response models and application to population PKPD analysis. J Pharmacokinet Pharmacodyn 2009 Aug; 36 (4): 341-51
37. Ng CM, Stefanich E, Anand BS, et al. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006 Jan; 23 (1): 95-103 (Pubitemid 43214665)
38. Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007 May; 63 (5): 548-61 (Pubitemid 46632569)
39. Retlich S, Duval V, Graefe-Mody U, et al. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010 Aug; 50 (8): 873-85
40. Tang C, Prueksaritanont T. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target. Pharm Res 2011 Oct; 28 (10): 2447-57
41. Lowe PJ, Tannenbaum S, Wu K, et al. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 2009 Mar; 106 (3): 195-209
42. Bhatia A, Kast RE. Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease [letter]. J Rheumatol 2007; 34 (2): 447-9
43. Granneman RG, Zhang Y, Noertersheuser PA, et al. Pharmacokinetic/ pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA) in rheumatoid arthritis (RA) patients during phase II/III clinical trials [abstract]. American College of Rheumatology Annual Scientific Meeting; 2003 Oct 24-28; Orlando (FL)
44. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009 Apr; 27 (4): 331-7
45. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factoralpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 Apr; 96 (1): 146-51 (Pubitemid 24213812)
46. Ragab HM, Abd El Maksoud N, Farid Roaiah MM. Biochemical significance of proinflammatory cytokines in psoriasis vulgaris among Egyptian patients. J Amer Sci 2010; 6 (10): 423-9
47. Moreau E, Philippe J, Couvent S, et al. Interference of soluble TNF-alpha receptors in immunological detection of tumor necrosis factor-alpha. Clin Chem 1996 Sep; 42 (9): 1450-3 (Pubitemid 26300244)